{Reference Type}: Journal Article
{Title}: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
{Author}: García-Campelo R;Sullivan I;Arriola E;Insa A;Juan Vidal O;Cruz-Castellanos P;Morán T;Reguart N;Zugazagoitia J;Dómine M;
{Journal}: Clin Transl Oncol
{Volume}: 25
{Issue}: 9
{Year}: 2023 Sep 7
{Factor}: 3.34
{DOI}: 10.1007/s12094-023-03216-3
{Abstract}: Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum-etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care.